New Targeted Therapies for HER2-Positive Metastatic Breast Cancer: Downloadable Slides

Expert slides from CCO workshops on HER2-targeted agents for HER2-positive metastatic breast cancer, including CNS metastases and HER2-low disease.
Sara Hurvitz, MD, FACP
Sara Tolaney, MD, MPH
Format: Microsoft PowerPoint (.ppt)
File Size: 5.05 MB
Released: September 23, 2020

Acknowledgements

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Puma Biotechnology, Inc.
Seattle Genetics

Related Content

In slides from Clinical Care Options (CCO), experts provide insights on HER2, HER3, and TROP2 testing and targeted treatment in breast and GI cancers

Mark D. Pegram, MD
Program Director
Axel Grothey Headshot Axel Grothey, MD Michael F. Press, MD, PhD
Released: October 29, 2020

Downloadable slideset with key data from the 2020 ESMO Virtual Congress created by Clinical Care Options (CCO)

Yelena Y. Janjigian, MD Joyce O'Shaughnessy, MD Elizabeth R. Plimack, MD, MS person default Vamsidhar Velcheti, MD Released: October 23, 2020

Downloadable PDF to gain expert perspectives on managing patients with breast cancer during the COVID-19 pandemic, from Clinical Care Options (CCO)

Harold J. Burstein, MD, PhD Hope S. Rugo, MD Released: October 6, 2020

From Clinical Care Options (CCO), watch video of an expert discussion of HER2-, HER3-, and TROP2-targeted agents for metastatic breast cancer

Mark D. Pegram, MD
Program Director
Physicians: maximum of 0.75 AMA PRA Category 1 Credits ABIM MOC: maximum of 0.75 Medical Knowledge MOC point(s) ABPath MOC: maximum of 0.75 Lifelong Learning (Part II) and Self-Assessment Module (SAM) point(s) Released: September 29, 2020 Expired: September 28, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue